Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glutamine dipeptide in surgical ICU patients
NCT00248638Phase 3Completed
- Sponsor
- Emory University
- Start
- Sep 2006
- Primary completion
- Dec 2012
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of alanyl glutamine in critical illness (2 arms), sponsored by Emory University. Primary endpoints: Hospital Mortality Rate up to 6 months and Percentage of Patients Who do Not Develop Hospital Infections up to 6 months. Started Sep 2006; status: completed.
02
Drugs
alanyl glutamine
03
Conditions
critical illness
Beyond the preview
Go deeper on NCT00248638.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00248638.